PARP1 and tuberculosis: Since PZA has negligible bactericidal but potent anti-inflammatory activity in human TB patients32, our data collectively suggest that PARP1 inhibition may be a key component of PZA’s mechanism of action underlying its unique treatment-shortening ability in TB therapy.